Zobrazeno 1 - 10
of 55
pro vyhledávání: ''
Autor:
Anas Gazzah, Pilar Garrido, Alexis B. Cortot, Jaafar Bennouna, Melissa Lynne Johnson, Maciej Gil, Haruyasu Murakami, Benjamin Besse
Publikováno v:
Lung Cancer. 142:63-69
Objectives Efficacy and safety of necitumumab when combined with pembrolizumab was assessed in patients with Stage IV non-small cell lung cancer (NSCLC) of squamous and nonsquamous histology, who had progressed after treatment with a platinum-based d
Publikováno v:
Lung Cancer. 135:116-122
Objectives The utility of malignant pleural effusion (MPE) as a source for determining EGFR mutations to guide EGFR TKI therapy in advanced adenocarcinoma of the lung remains unclear. This study compared MPE, plasma and tumor tissues as sources of bi
Autor:
Jessica A. Hellyer, Sukhmani K. Padda, Joel W. Neal, Millie Das, Heather A. Wakelee, Henning Stehr, Maximilian Diehn, Kavitha Ramchandran
Publikováno v:
Lung Cancer. 134:42-45
Objectives For patients with Epidermal Growth Factor Receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), frontline EGFR-tyrosine kinase inhibitor (TKI) therapy compared to chemotherapy improves outcomes. However, resistance to these agents un
Publikováno v:
Lung Cancer. 133:103-109
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as first-line standard treatment for advanced lung adenocarcinoma with mutant EGFR. Nevertheless, few studies have demonstrated the efficacy of first- and s
Autor:
Katsuyuki Hotta, Kadoaki Ohashi, Katsuyuki Kiura, Toshio Kubo, Yoshinobu Maeda, Kammei Rai, Hisaaki Tanaka, Masahiro Tabata, Eiki Ichihara, Kiichiro Ninomiya
Publikováno v:
Lung Cancer. 132:54-58
Background Osimertinib is a tyrosine kinase inhibitor (TKI) that is an essential agent for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). However, there is no established strategy for treatment fol
Autor:
Hiroaki Akamatsu, Daichi Fujimoto, Kazuhiko Nakagawa, Yasuhiro Koh, Akihiro Bessho, Nobuyuki Yamamoto, Satoshi Morita, Koichi Azuma, Isamu Okamoto
Publikováno v:
Lung Cancer. 131:128-133
Liquid biopsy has been approved as an optional method to detect epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). However, the clinical significance of its utility for monitoring the disease remains elusive. WJO
Autor:
Xiaojuan Zhang, Xuanxuan Zheng, Jinpo Yang, Peng Li, M. Zhang, Xiangtao Yan, Zhiyong Ma, Huijuan Wang, Guowei Zhang
Publikováno v:
Lung Cancer. 128:6-12
Objective: The objective of this study was to investigate whether first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in combination with chemotherapy improves the prognosis of patients with advanced non-sm
Autor:
Alexis B. Cortot, David Planchard, Hélène Doubre, Bénédicte Mastroianni, Sylvestre Le Moulec, Florian Guisier, Lionel Falchero, Jennifer Arrondeau, Aldo Renault, Isabelle Monnet, Laurent Greillier, Marie Wislez, L. Gérinière, Jean Bernard Auliac, Chantal Decroisette, Maurice Pérol, Eric Pichon, Catherine Daniel, Christos Chouaid, Roland Schott
Publikováno v:
Lung Cancer
Lung Cancer, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, Elsevier, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, Elsevier, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
International audience; Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in clinical trials. However, data on efficacy of osimert
Autor:
Miyako Satouchi, Ken Uchibori, Motoko Tachihara, Chiyuki Kokan, Yoshiko Urata, Keisuke Aoe, Kazuyuki Kobayashi, Kentaro Iwanaga, Akemi Sato, Naoko Sueoka-Aragane, Satoshi Morita, Tomonori Hirashima, Nobuyuki Katakami, Shunichi Negoro, Takako Inoue, Fumio Imamura, Masahide Mori
Publikováno v:
Lung Cancer. 124:65-70
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (i.e., EGFR-TKIs) improve the survival of lung cancer patients harboring EGFR mutations. Despite the initial efficacy of EGFR-TKIs, the disease progression caused by acquir
Autor:
Melania Pintilie, Shingo Sakashita, Ming-Sound Tsao, Ronald Feld, Suzanne Kamel-Reid, Frances A. Shepherd, Pascale Tomasini, C. Mascaux, Catherine Labbé, Kevin Jao, David M. Hwang, Penelope A. Bradbury, Geoffrey Liu, Natasha B. Leighl, Gregorz J. Korpanty
Publikováno v:
Lung Cancer. 123:22-29
Introduction Somatic mutations are becoming increasingly important biomarkers for treatment selection and outcome in patients with non-small-cell lung cancer (NSCLC). The role of multiple somatic mutations in early-stage NSCLC is unclear. Methods Tis